Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;8(12):746.
doi: 10.21037/atm-20-611.

Pharmacological treatment of neuropsychiatric symptoms of dementia: a network meta-analysis protocol

Affiliations

Pharmacological treatment of neuropsychiatric symptoms of dementia: a network meta-analysis protocol

Yu-Yuan Huang et al. Ann Transl Med. 2020 Jun.

Abstract

Background: Neuropsychiatric symptoms (NPS) of dementia are a common issue in dementia patients which can lead to poor medical and functional outcomes. Pharmacological interventions are its treatment of choice. However, whether to use pharmacological treatments in this population and which drug should be preferred remain controversial. We therefore aimed to compare and rank pharmacological interventions for NPS according to their efficacy and acceptability profiles by quantifying information from randomized controlled trials (RCTs).

Methods: We will include all RCTs reported as double-blind and comparing one active drug with another or with placebo that compare cholinesterase inhibitors (ChEIs), N-methyl-D-aspartic acid (NMDA) receptor modulators, antipsychotics, antidepressants, and mood stabilisers. Studies will be retrieved by searching electronic databases, including Cochrane Central Register of Controlled Trials, PubMed, MEDLINE, Clinicaltrial.govs, EMBASE, and with no date or language restrictions. The primary outcomes were efficacy (change in overall symptoms) and acceptability (all-cause discontinuation). The network meta-analysis (NMA) will be conducted in R software within a Bayesian framework. The quality of evidence will be evaluated using the Cochrane risk of bias tool, and the GRADE approach. We will conduct subgroup analyses to assess the robustness of our findings.

Results: The results of this study will be published in a peer-reviewed journal.

Conclusions: This systematic review will synthesize the available evidence on the comparative efficacy of different pharmacological approaches in the management of overall NPS, agitation, psychosis, apathy and depressive symptoms in dementia patients. The results of the present NMA will influence evidence-based treatment decisions for clinicians.

Keywords: Dementia; neuropsychiatric symptoms (NPS); pharmacological; randomized controlled trial.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-611). JTY serves as an unpaid Associate Editor-in-Chief of Annals of Translational Medicine from Jun 2019 to May 2024. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Proposed flow diagram to depict the search process.

References

    1. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet 2017;390:2673-734. 10.1016/S0140-6736(17)31363-6 - DOI - PubMed
    1. Mathys M. Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder. Ment Health Clin 2018;8:284-93. 10.9740/mhc.2018.11.284 - DOI - PMC - PubMed
    1. Aalten P, de Vugt ME, Lousberg R, et al. Behavioral problems in dementia: a factor analysis of the neuropsychiatric inventory. Dement Geriatr Cogn Disord 2003;15:99-105. 10.1159/000067972 - DOI - PubMed
    1. Nowrangi MA, Lyketsos CG, Rosenberg PB. Principles and management of neuropsychiatric symptoms in Alzheimer's dementia. Alzheimers Res Ther 2015;7:12. 10.1186/s13195-015-0096-3 - DOI - PMC - PubMed
    1. Lai MK, Tsang SW, Esiri MM, et al. Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease. Psychopharmacology (Berl) 2011;213:431-9. 10.1007/s00213-010-1936-2 - DOI - PubMed